Sage soars as postpartum depression drug moves closer to approval

(Reuters) - Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news